You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代中藥集團(01643.HK):上半年純利4412萬元 同比增加10.5%
格隆匯 08-26 18:55

格隆匯8月26日丨現代中藥集團(01643.HK)發佈公吿,截至2021年6月30日止六個月,收益為人民幣1.718億元,同比增加約8.8%;毛利為人民幣7860萬元,同比增加約10.4%;公司擁有人應占期內溢利人民幣4412萬元,同比增加約10.5%;每股基本及攤薄盈利為人民幣7.43分。

公吿表示,集團於該期間錄得綜合收益約人民幣1.718億元。收益增加由於現有分銷商的目標推廣策略,主要受銷售三大產品(即補腎填精丸、金匱腎氣丸及氣血雙補丸)產生的收益增加所帶動。該期間,該三大產品銷售額增加緩和了具有治療2019新冠病毒病症及╱或相似病症目標療效的兩大產品(即加味藿香正氣丸及清瘟解毒丸)需求下跌的影響。

集團目前已建立具有80多名經銷商組成的分銷網絡,覆蓋中國約40個城市,並由逾35名具有傳統中醫藥行業相關經驗的市場推廣人員提供服務及管理。集團相信在可預見的未來,集團的分銷網絡及經銷商模式將繼續支援業務經營的進一步發展。此外,集團亦認為,分銷網絡不僅有助於將業務營運從東北擴張至中國其他地區,亦能讓集團頗為深入及廣泛地滲透中國東北,而由於集團在中國東北已建立覆蓋點及該地區人口龐大,當地成為集團的戰略目標。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account